Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Misses Estimates By $0.46 EPS

Key Points

• Q4 miss: Dianthus reported EPS of ($1.43), missing estimates by $0.46, while revenue of $0.57M beat expectations but the company showed an extremely negative net margin (4,106%) and negative return on equity.
• Clinical de‑risking: The Phase 3 CAPTIVATE trial reached an early "GO" decision after an interim responder analysis, and Dianthus will keep the 300mg dose while engaging regulators to remove the 600mg option for claspebrubart.
• Market reaction and analyst support: Shares surged ~26.6% to $82.54 on heavy volume following the clinical news, with several firms raising price targets (e.g., Truist to $110, Jefferies to $81) and a consensus rating of "Moderate Buy" (average target $73.50).

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.46), FiscalAI reports. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million.

Dianthus Therapeutics Stock Up 26.6%

Shares of NASDAQ:DNTH traded up $17.34 during trading on Monday, reaching $82.54. The stock had a trading volume of 2,396,274 shares, compared to its average volume of 846,780. The business has a fifty day moving average price of $48.42 and a 200-day moving average price of $40.78. The stock has a market cap of $3.57 billion, a P/E ratio of -23.72 and a beta of 1.56. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $84.86.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtus Investment Advisers LLC lifted its holdings in shares of Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company's stock valued at $260,000 after acquiring an additional 416 shares in the last quarter. Royal Bank of Canada increased its holdings in Dianthus Therapeutics by 36.9% in the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company's stock valued at $82,000 after purchasing an additional 542 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after purchasing an additional 618 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Dianthus Therapeutics in the fourth quarter valued at about $40,000. Finally, Deutsche Bank AG lifted its stake in shares of Dianthus Therapeutics by 9.3% during the fourth quarter. Deutsche Bank AG now owns 15,831 shares of the company's stock worth $652,000 after purchasing an additional 1,343 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Jefferies Financial Group increased their price target on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the company a "buy" rating in a report on Monday, February 2nd. HC Wainwright upped their target price on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a "buy" rating in a research report on Monday, November 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Truist Financial boosted their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a "buy" rating in a research note on Monday. Finally, Wedbush upped their price target on Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an "outperform" rating in a report on Wednesday, February 11th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $73.50.

More Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early GO decision in Phase 3 CAPTIVATE — Dianthus announced an early "GO" decision following an interim responder analysis: the trial hit the GO criteria of 20 confirmed responders with fewer than 40 planned Part A completers. The company will keep the Part A dose at 300mg/2mL S.C. Q2W and plans to engage regulators about removing the 600mg/4mL option — a substantive clinical/regulatory de‑risking step for claseprubart. Article Title
• Positive Sentiment: Analyst upgrade / price-target lift — Truist raised its price target from $63 to $110 and maintained a "buy" rating, signalling increased upside expectations and likely supporting buying interest. Article Title
• Neutral Sentiment: Investor access / upcoming commentary — Dianthus hosted (and scheduled) a conference call and webcast to discuss the interim responder analysis results, which should provide additional color and could drive intraday volatility depending on management tone and Q&A. Article Title
• Neutral Sentiment: Market commentary / valuation focus — Recent write-ups evaluate DNTH after a strong run-up in the share price; these pieces can amplify debate on whether current valuation already prices the program successes. Article Title
• Negative Sentiment: Q4 earnings miss and widening loss — Dianthus reported Q4 EPS of ($1.43) vs. consensus (~$0.97 loss), missing estimates by ~$0.46; revenue was $0.57M (above an estimate of $0.40M) but the company posted extremely negative margins and ROE. The larger-than-expected loss raises near-term profitability concerns and could limit upside despite the clinical news. Article Title

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.